Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
15
self-reported 2–10 band
Founded
2021
5 years
Legal entities
1
ACRA
Office countries
1
1 address
Funding rounds
1
Seed · May 2024 · US$ 4.0M
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
AURISTONE PTE. LTD.Entity record →
UEN202125976R
Legal entities
Show as table · Auristone Pte Ltd: 1 registry entity
| AURISTONE PTE. LTD. | UEN 202125976R |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Auristone is an Asian-based epigenomic profiling company powered with data analytics capabilities and extensive epigenomic know-how. We use our comprehensive portfolio of Asian epigenomic database to power data-driven drug and biomarker discoveries.
EPI-Call™ is our Flagship second generation Next Generation Sequencing (NGS) test. In addition to genomic information (DNA-seq), EPI-Call™ further provides epigenomic information around the tumour micro-environment and predicts patient response to immunotherapy. EPI-Call™ is the pragmatic choice to aid physicians in deciding the best treatment option for their patients.
We are committed to supporting clinical and academic epigenomic research, and moving such research outcomes into the clinical setting. Driven by our aspiration to improve the quality of life for patients through better treatment, we are continuously seeking ways to bring our technologies to our clinical and academic partners.
For more information on the company, drop us a line at enquiry@auristone.com or visit our website at www.auristone.com.
Specialties
All 5 specialties
- Epigenomics
- Gastric Cancer
- Histone Modifications
- Oncology
- Biotechnology
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
Addresses
- SG73 Ayer Rajah Crescent, #02-10, Singapore 139952; SingaporePrimary
Grid intelligence Members
Funding
Rounds1
Round typeSeed · venture round
Amount (USD)4,000,000
Stage rank2
Investors named1
Since last round1 yr 8 mo
Funding
Show as table · 1 funding round
| Rounds | 1 |
|---|---|
| Axis | 2021 to 2026 |
| Seed · 2 May 2024 | US$ 4.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Auristone Pte Ltd?
One Singapore entity on ACRA. AURISTONE PTE. LTD. (UEN 202125976R), high confidence.
How many people work at Auristone Pte Ltd?
The record holds 15 counted staff profiles at January 2026, above the self-reported 2–10 band.
Where does Auristone Pte Ltd have offices?
One address on record, Singapore only. Primary: 73 Ayer Rajah Crescent, #02-10, Singapore 139952, Singapore.
Has Auristone Pte Ltd raised funding?
One round. Latest 2 May 2024: Seed, US$4,000,000, investor Elev8.VC.
What does Auristone Pte Ltd list as its specialties?
Five tags on the brand's own list, among them oncology and biotechnology.
Which companies are listed alongside Auristone Pte Ltd?
Five peer profiles on record: Allozymes and AVATAMED.